Thromboembolic event rate in paroxysmal and persistent atrial fibrillation: data from the GISSI-AF trial. - Wikidata - awgldk - TriplyDB

Thromboembolic event rate in paroxysmal and persistent atrial fibrillation: data from the GISSI-AF trial.

Thromboembolic event rate in paroxysmal and persistent atrial fibrillation: data from the GISSI-AF trial.

http://www.wikidata.org/entity/Q34668483

about

Stroke Event Rates and the Optimal Antithrombotic Choice of Patients With Paroxysmal Atrial Fibrillation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Thromboembolic risk and effect of oral anticoagulation according to atrial fibrillation patterns: A systematic review and meta-analysis Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial.Effects of body mass index on risks for ischemic stroke, thromboembolism, and mortality in Chinese atrial fibrillation patients: a single-center experience.ANMCO Position Paper: direct oral anticoagulants for stroke prevention in atrial fibrillation: clinical scenarios and future perspectives.Type of Atrial Fibrillation and Clinical Outcomes in Patients Undergoing Transcatheter Aortic Valve Replacement.Incidence of ischemic stroke and systemic embolism in patients with hypertrophic cardiomyopathy, nonvalvular atrial fibrillation, CHA2DS2-VASc score of ≤1 and without anticoagulant therapy.Association of atrial fibrillation with gene polymorphisms of connexin 40 and angiotensin II receptor type 1 in Chongming adults of Shanghai.Effect of sinus rhythm restoration on markers of thrombin generation in atrial fibrillation.Temporal pattern/episode duration-based classification of atrial fibrillation as paroxysmal vs. persistent: is it time to develop a more integrated prognostic score to optimize management?3D-computed tomography to compare the dimensions of the left atrial appendage in patients with normal sinus rhythm and those with paroxysmal atrial fibrillation.Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES.

P2860

Q26771564-EF6B9398-DC3A-4180-BE6D-31B0998D85D0 Q29994528-9996F628-59D6-4478-BF54-7BD4C59A9A12 Q35036404-954D7859-2B62-4471-8521-6870F1CB266B Q35305757-46D116EC-093F-4AB1-BEF5-EF155502F21F Q38650658-09A62AAB-9505-413E-8923-F3E115565B34 Q40049684-1157C2E5-BC34-4587-B146-6B25DC499387 Q40672562-D0B8F7D6-C8DD-4F24-87F8-45CDA6B64A9D Q43183347-1BDD948A-5A99-419F-A469-A2B9E6F80802 Q47106384-08838559-3E83-410B-B679-179919994FA5 Q47827668-B9A240D2-74C5-4AB5-BA2D-B43296A46D03 Q48250577-E031C627-57DA-4A4E-BA51-56ACA7E21DFB Q48565298-C27596A0-713C-4DB8-9543-E42DD4D1E6B1

P2860

Thromboembolic event rate in paroxysmal and persistent atrial fibrillation: data from the GISSI-AF trial.

http://www.wikidata.org/entity/Q34668483

description

2013 nî lūn-bûn

@nan

2013 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Thromboembolic event rate in p ...... data from the GISSI-AF trial.

@ast

Thromboembolic event rate in p ...... data from the GISSI-AF trial.

@en

Thromboembolic event rate in p ...... data from the GISSI-AF trial.

@nl

type

label

Thromboembolic event rate in p ...... data from the GISSI-AF trial.

@ast

Thromboembolic event rate in p ...... data from the GISSI-AF trial.

@en

Thromboembolic event rate in p ...... data from the GISSI-AF trial.

@nl

prefLabel

Thromboembolic event rate in p ...... data from the GISSI-AF trial.

@ast

Thromboembolic event rate in p ...... data from the GISSI-AF trial.

@en

Thromboembolic event rate in p ...... data from the GISSI-AF trial.

@nl

P1433

Q34668483-5EFD6EEA-1C7D-47C6-A50C-861FD92A9E26

P1476

Q34668483-5B7C0E47-3492-452B-851C-93538DDCEC73

P2093

Q34668483-0172E120-D0F1-4B44-86CE-7C623227B066

Q34668483-0A4C55A7-EE77-4243-9C6F-7DDB086BF141

Q34668483-3062F678-D6CD-49FE-82CC-B8E2F2FDDCBC

Q34668483-34BA4396-8D64-4408-8152-C9B0500CA8BC

Q34668483-3736188A-5CE0-4FA7-B0A6-D6E711206817

Q34668483-3AE1F35D-E28F-4C7B-B836-1ABB731E050C

Q34668483-54094B2C-D495-45FA-9929-D2AC42AC628C

Q34668483-72467509-CDE4-4126-AF9E-F3AC4FAEDC3B

Q34668483-97A89A72-4582-4886-85DD-CA317A618F40

Q34668483-E8E2CD50-1EC9-40C9-9AB7-1299EF193ED5

P2860

Q34668483-115D60ED-3BDD-4CD6-AC5D-860EACD1C0F6

Q34668483-29069BF3-5E39-4577-8E89-DEA961C834E2

Q34668483-3D272BD2-04C6-4463-9E0A-006803AAE416

Q34668483-3F89A3AE-CEA4-4C1B-976E-76633B6F3965

Q34668483-41CA60E1-9716-4CFF-B285-37063C1DA1D1

Q34668483-442335E7-1022-4053-937C-DC2158341256

Q34668483-48935E15-9B4F-4724-AE05-216DE0CCB742

Q34668483-4F825814-C3DE-41B6-9926-CEBE133F9C2A

Q34668483-537809C5-4F2B-4B89-A6A3-360161BB86D4

Q34668483-5BC180D6-97A3-44FE-A2C8-725049419A2C

P2888

Q34668483-69B0A1CB-2264-42FB-8723-80C43E79C50B

P304

Q34668483-24D8ECEB-33C9-4857-BC64-F727011EE470

P31

Q34668483-EDE76D0D-FE83-4E97-8B37-9F676FDC4835

P356

Q34668483-038C587E-C53D-4000-9601-69F21876B9A6

P478

Q34668483-C8497C5A-4A4F-4148-8AAE-95006CDE79B5

P50

Q34668483-DD332085-A681-4762-BB05-311015AA7D77

P577

Q34668483-BBE344AD-3E48-49E5-A629-2800F51B0414

P5875

Q34668483-8D47737D-36B9-444C-9464-FA0C3D014DB8

P6179

Q34668483-858E809A-A401-4276-8864-B09167C56219

P698

Q34668483-98BA118B-F506-4AC7-AD50-28214B148886

P921

Q34668483-3C0B356C-11B0-402F-B1A8-E1837907E1EA

P932

Q34668483-0E68BF80-84FF-4291-8DC3-17628E0A888C

P356

1471-2261-13-28

P1433

BMC Cardiovascular Disorders

P1476

Thromboembolic event rate in p ...... data from the GISSI-AF trial.

@en

P2093

Chiara Favero

http://www.w3.org/2001/XMLSchema#string

Franco Cosmi

http://www.w3.org/2001/XMLSchema#string

GISSI-AF investigators

http://www.w3.org/2001/XMLSchema#string

Gianna Fabbri

http://www.w3.org/2001/XMLSchema#string

Glauco Cappellini

http://www.w3.org/2001/XMLSchema#string

Lidia Staszewsky

http://www.w3.org/2001/XMLSchema#string

Luigi Andrea Moroni

http://www.w3.org/2001/XMLSchema#string

Marcello Disertori

http://www.w3.org/2001/XMLSchema#string

Maria Grazia Franzosi

http://www.w3.org/2001/XMLSchema#string

Roberto Latini

http://www.w3.org/2001/XMLSchema#string

P2860

Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation

ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation

Validation of Clinical Classification Schemes for Predicting Stroke

Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke Prevention in Atrial Fibrillation Investigators.

Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation.

Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: the AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study.

Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation.

The net clinical benefit of warfarin anticoagulation in atrial fibrillation.

Prevalence and predictors of warfarin use in patients with atrial fibrillation at low or intermediate risk and relation to thromboembolic events.

P2888

1471-2261-13-28

P304

28

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2261-13-28

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P50

Aldo P Maggioni

P577

2013-04-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236183288

http://www.w3.org/2001/XMLSchema#string

P6179

1011655469

http://www.w3.org/2001/XMLSchema#string

P698

23586654

http://www.w3.org/2001/XMLSchema#string

P921

thromboembolism

P932

3639147

http://www.w3.org/2001/XMLSchema#string